Answers are grounded in this paper and cite their sources.
In an adaptive seamless phase II/III clinical trial interim analysis, data are used for treatment selection, enabling resources to be focused on comparison of more effective treatment(s) with a control. In this paper, we compare two methods recently proposed to enable use of short-term endpoint data for decision-making at the interim analysis. The comparison focuses on the power and the probability of correctly identifying the most promising treatment. We show that the choice of method depends on how well short-term data predict the best treatment, which may be measured by the correlation between treatment effects on short- and long-term endpoints.
No takes yet. Share an insight, caveat, or question.
Kunz et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: